Anthera Pharmaceuticals, Inc. (ANTH) to Release Quarterly Earnings on Monday
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) is scheduled to be issuing its quarterly earnings data after the market closes on Monday, November 6th. Analysts expect the company to announce earnings of ($0.91) per share for the quarter.
Anthera Pharmaceuticals (NASDAQ:ANTH) last announced its earnings results on Wednesday, August 9th. The biopharmaceutical company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($1.09) by $1.12. On average, analysts expect Anthera Pharmaceuticals to post $-3.64 EPS for the current fiscal year and $-3.42 EPS for the next fiscal year.
Shares of Anthera Pharmaceuticals, Inc. (ANTH) traded down 8.72% during midday trading on Monday, hitting $1.57. 190,022 shares of the stock were exchanged. The firm has a 50-day moving average price of $1.54 and a 200-day moving average price of $1.49. The company’s market cap is $17.12 million. Anthera Pharmaceuticals, Inc. has a 12-month low of $1.20 and a 12-month high of $22.48.
COPYRIGHT VIOLATION WARNING: This news story was posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/30/anthera-pharmaceuticals-inc-anth-to-release-quarterly-earnings-on-monday.html.
Several research firms have recently commented on ANTH. Zacks Investment Research raised shares of Anthera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.00 price target for the company in a report on Tuesday, October 10th. ValuEngine raised shares of Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price target on shares of Anthera Pharmaceuticals in a report on Tuesday, September 19th. Finally, Jefferies Group LLC reissued a “hold” rating and set a $1.75 target price (down from $2.25) on shares of Anthera Pharmaceuticals in a research note on Friday, August 11th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company. Anthera Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $5.11.
Anthera Pharmaceuticals Company Profile
Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.
Receive News & Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.